Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Mitsubishi Tanabe Pharma
Pharma
China IIT, Daiichi Sankyo-AZ, Leo-Tanabe—Fierce Pharma Asia
China's alternative trial pathway draws scrutiny. AZ and Daiichi Sankyo's phase 3 lung cancer win. Tanabe's licensing deal. And more.
Donavyn Coffey
Aug 21, 2026 9:00am
AZ's China deals, Kailera-Hengrui—Fierce Pharma Asia
Jul 10, 2026 8:51am
Tanabe to sell manufacturing unit, rights to 17 meds to Towa
Jul 7, 2026 8:54am
Astellas, Takeda, Chugai and more—Fierce Pharma Asia
Jan 23, 2026 9:05am
China biotech deals, Shionogi's ALS buy—Fierce Pharma Asia
Jan 9, 2026 3:00am
ALS med Radicava to change hands as Shionogi inks $2.5B buyout
Dec 22, 2025 10:10am
